Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 31, 2022 06:00 ET | Source: Eledon Pharmaceuticals, Inc.

Eledon Announces Positive Topline Results from Phase 2a Trial of Tegoprubart Demonstrating Safety, Target Engagement, and Biomarker Response in Patients Living with Amyotrophic Lateral Sclerosis

Tegoprubart was well-tolerated, with no drug-related serious adverse eventsDose dependent target engagement was demonstrated, and ALS associated pro-inflammatory biomarkers were both observed and...
April 18, 2022 16:05 ET | Source: Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals to Participate in 18th Annual Noble Capital Markets Investor Conference

IRVINE, Calif., April 18, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
April 14, 2022 16:05 ET | Source: Eledon Pharmaceuticals, Inc.

Eledon to Host Virtual R&D Day on Thursday, April 28, 2022

IRVINE, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
February 14, 2022 08:00 ET | Source: Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals Provides Corporate Update and 2022 Outlook

Completed enrollment of all four cohorts in ongoing Phase 2a study with tegoprubart (AT-1501) in Amyotrophic Lateral Sclerosis (ALS) Announces USAN Approval of Generic Name “tegoprubart” for lead...
February 08, 2022 16:05 ET | Source: Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals to Participate in 11th Annual SVB Leerink Global Healthcare Conference

IRVINE, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...